These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 10197087)
1. Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide. Kaltsas GA; Putignano P; Mukherjee JJ; Satta MA; Lowe DG; Britton KE; Monson JP; Grossman AB; Besser GM Clin Endocrinol (Oxf); 1998 Nov; 49(5):685-9. PubMed ID: 10197087 [TBL] [Abstract][Full Text] [Related]
2. Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide. Isidori AM; Kaltsas G; Frajese V; Kola B; Whitelocke RA; Plowman PN; Britton KE; Monson JP; Grossman AB; Besser GM J Clin Endocrinol Metab; 2002 Apr; 87(4):1627-33. PubMed ID: 11932293 [TBL] [Abstract][Full Text] [Related]
3. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue. Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Zuetenhorst JM; Hoefnageli CA; Boot H; Valdés Olmos RA; Taal BG Nucl Med Commun; 2002 Aug; 23(8):735-41. PubMed ID: 12124478 [TBL] [Abstract][Full Text] [Related]
5. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840 [TBL] [Abstract][Full Text] [Related]
6. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063 [TBL] [Abstract][Full Text] [Related]
7. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676 [TBL] [Abstract][Full Text] [Related]
8. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors. Bomanji J; Mather S; Moyes J; Ellison D; Grossman A; Britton KE; Besser GM J Nucl Med; 1992 Jun; 33(6):1121-4. PubMed ID: 1597726 [TBL] [Abstract][Full Text] [Related]
9. Octreotide scanning for carcinoid tumours. Critchley M Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023 [TBL] [Abstract][Full Text] [Related]
10. Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report. Dworakowska D; Gueorguiev M; Laji K; Grossman AB Endokrynol Pol; 2008; 59(4):342-7. PubMed ID: 18777505 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146 [TBL] [Abstract][Full Text] [Related]
12. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927 [TBL] [Abstract][Full Text] [Related]
13. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571 [TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis. Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133 [TBL] [Abstract][Full Text] [Related]
15. 111In-pentetreotide and 123I-MIBG for detection and resection of lymph node metastases of a carcinoid not visualized by CT, MRI or FDG-PET. Yüksel M; Eziddin S; Ladwein E; Haas S; Biersack HJ Ann Nucl Med; 2005 Oct; 19(7):611-5. PubMed ID: 16363628 [TBL] [Abstract][Full Text] [Related]
16. Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. Musi M; Carbone RG; Bertocchi C; Cantalupi DP; Michetti G; Pugliese C; Virotta G Lung Cancer; 1998 Nov; 22(2):97-102. PubMed ID: 10022217 [TBL] [Abstract][Full Text] [Related]
17. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination. Zuetenhorst H; Taal BG; Boot H; Valdes Olmos R; Hoefnagel C Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1157-64. PubMed ID: 10524647 [TBL] [Abstract][Full Text] [Related]
18. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953 [TBL] [Abstract][Full Text] [Related]
19. [111IN-octreotide and 123I-MIBG scintigraphy in the diagnosis of small intestinal carcinoid tumors--results of a comparative investigation]. Dresel S; Tatsch K; Zachoval R; Hahn K Nuklearmedizin; 1996 Apr; 35(2):53-8. PubMed ID: 8721576 [TBL] [Abstract][Full Text] [Related]
20. L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging. Jager PL; Meijer WG; Kema IP; Willemse PH; Piers DA; de Vries EG J Nucl Med; 2000 Nov; 41(11):1793-800. PubMed ID: 11079485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]